FIV gp40七肽重复区基因的克隆表达及其产物的纯化

本研究利用Leam Coil-VMF程序预测到FIV Env蛋白gp40存在两个七肽重复区(Heptad repeat,HR1和HR2),对包括HR1和HR2在内的部分gp40胞外区基因(称为HRI-HR2)进行了人工合成,以此基因为模板获得了HR1和HR2基因的扩增产物,同时构建了用氨基酸连接子SGGRGG将HR1和HR2连接起来的串联基因(即HRIlinkerHR2,命名为2-Helix),采用人肠杆菌GST融合表达系统对HR1、HR2和2-Helix蛋白进行了表达,并对2-Helix进行了纯化。同时利用凝胶过滤层析证明2-Helix在PBS缓冲系统中以寡聚体的形式存在。     

新城疫病毒囊膜糖蛋白七肽重复区的融合作用

在新城疫病毒（Newcastle diseasevirus,NDV）膜融合的过程中融合糖蛋白（Fusion protein,F）的两段七肽重复区（Heptad repeat,HR）发挥着重要作用。这两段七肽重复区能够形成反相平行的六螺旋束结构,这被认为是融合蛋白融合后构象的核心结构。对融合作用的深入系统研究将有助于膜融合病毒的防控。     

FIV gp40 七肽重复区基因的克隆表达及其产物的纯化

本研究利用Learn Coil-VMF程序预测到FIV Env蛋白gp40存在两个七肽重复区(Heptad repeat,HR1和HR2),对包括HR1和HR2在内的部分gp40胞外区基因(称为HR1-HR2)进行了人工合成,以此基因为模板获得了HR1和HR2基因的扩增产物,同时构建了用氨基酸连接子SGGRGG将HR1和HR2连接起来的串联基因(即HR1linkerHR2,命名为2-Helix),采用大肠杆菌GST融合表达系统对HR1、HR2和2-Helix蛋白进行了表达,并对2-Helix进行了纯化.同时利用凝胶过滤层析证明2-Helix在PBS缓冲系统中以寡聚体的形式存在.     

ZAP融合蛋白抑制HIV病毒模型的构建及功能分析

ZAP是一种抗病毒因子,能够特异性结合病毒RNA并招募细胞中的RNA酶降解所结合的靶RNA,从而抑制某些病毒的复制,如鼠白血病病毒(MLV)、辛德比斯病毒(SIN).ZAP对HIV病毒抑制作用并不明显.Tat和Rev是HIV编码的两种可以特异性结合HIVRNA的蛋白质,将它们与ZAP构建成融合蛋白,使得融合蛋白通过Tat或Rev结合HIVRNA并通过ZAP降解HIVRNA,从而抑制HIV假病毒载体携带基因的表达.这一结果为抑制HIV病毒提供了一个新思路,也支持了ZAP招募mRNA降解机器降解靶RNA的模型.     

HIV-1 gp41的酵母表面展示及表达优化

以His标签检测蛋白的表达, 利用酿酒酵母表面展示系统, 成功地将HIV-1 gp41片段锚定在酵母表面, 并检测到gp41的活性。以pMD18T-gp41为模板, 通过PCR技术克隆了gp41基因, 将gp41基因通过双酶切连接到载体pICAS-His上,构建了gp41酵母表面展示载体, 并将其转化至酿酒酵母(Saccharomyces cerevisiae)MT8-1中。重组菌经培养, 利用免疫荧光染色方法进行染色, 显微镜观察发现重组酵母细胞表面有绿色荧光, 流式细胞仪结果进一步证实gp41正确折叠展示于酵母细胞表面。采用不同浓度的葡萄糖培养基进行表达优化。当葡萄糖浓度为1%时, 82.46%的酵母细胞表达了gp41抗原; 随着葡萄糖浓度升高, 蛋白表达受到抑制。     

HIV-1 gp41的酵母表面展示及表达优化

以His标签检测蛋白的表达, 利用酿酒酵母表面展示系统, 成功地将HIV-1 gp41片段锚定在酵母表面, 并检测到gp41的活性。以pMD18T-gp41为模板, 通过PCR技术克隆了gp41基因, 将gp41基因通过双酶切连接到载体pICAS-His上,构建了gp41酵母表面展示载体, 并将其转化至酿酒酵母(Saccharomyces cerevisiae)MT8-1中。重组菌经培养, 利用免疫荧光染色方法进行染色, 显微镜观察发现重组酵母细胞表面有绿色荧光, 流式细胞仪结果进一步证实gp41正确折叠展示于酵母细胞表面。采用不同浓度的葡萄糖培养基进行表达优化。当葡萄糖浓度为1%时, 82.46%的酵母细胞表达了gp41抗原; 随着葡萄糖浓度升高, 蛋白表达受到抑制。     

新城疫病毒F蛋白中两段七肽重复序列的克隆和表达

从新城疫病毒 (NDV)中国强毒株F4 8E9和弱毒株长春株F蛋白的cDNA中亚克隆出两段七肽重复序列(HeptadRepeatRegion ,HR1,HR2 ) ,将HR1和HR2分别插入表达载体pGEX 6p 1,在大肠杆菌BL2 1(DE3 )中表达 ,将与载体中的GST(GlutathioneS Trasferase)融合表达的可溶性融合蛋白用GST亲和层析柱纯化。纯化的融合蛋白用蛋白酶酶切后 ,先用GST亲和层析柱除去GST ,再加热进一步纯化。纯化的HR1和HR2质谱分析其分子量 ,结果表明 ,强株的HR1和HR2的分子量分别为 7 10 3kD和 6 3 0 1kD ,弱株的HR1和HR2的分子量分别为 7 10 7kD和6 3 0 9kD ,强弱株HR1和HR2的分子量都基本一致。本工作为研究HR1、HR2的结构以及它们在NDV与宿主细胞融合中的作用奠定了基础。     

N端八肽重复区数目对人重组PrP与金属离子结合后的蛋白酶抗性及与tau蛋白结合能力的影响

人类朊病毒病中约10％～15％具有家族遗传特性,其中插入或缺失突变多发生于PrP蛋白N末端的八肽重复区域。运用PCR成功地构建并表达了含不同八肽重复数目的PrP蛋白,并观察八肽重复数目的增加对PrP与Cu^2＋等二价离子以及tau蛋白的相互作用的影响。实验结果显示：各种纯化后的PrP蛋白对常规浓度PK消化是敏感的,而与Cu^2＋共同孵育可使PrP蛋白的PK抗性增强;八肽重复序列的数目及Cu^2＋的浓度决定了PK抗性的出现和强弱。另外,MnH可诱导产生与CuH相似的结果,但其诱导效应似乎低于CuH,而Zn^2＋对PrP蛋白的PK抗性无影响。GST—tau包被的ELISA检测证实,重组的PrP呈现出明显的tau蛋白结合能力,并且与八肽重复序列的数量相关,重复序列数量越多,结合能力越强。这些结果提示,CuH诱导产生的PrP蛋白PK抗性是通过八肽重复序列区域产生的,并且直接与重复序列的数量相关。另外,PrP蛋白八肽重复序列的存在和数量直接影响PrP与tau蛋白的结合效应。除了八肽区域外,PrP蛋白其它区域似乎也具有一定的tau蛋白结合能力。     

HIV-1 gp41N端融合肽与脂膜作用的荧光及单分子层膜研究

我们以前的实验证明ＨＩＶ－１ｇｐ４１Ｎ端２３肽即融合肽ＨＩＶｗｔ能促融合,但它的突变体ＨＩＶＧｌｕ（２位Ｖ→Ｅ）却不能诱发融合。为了进一步研究多肽结构与功能的关系,我们用荧光及单分子层膜技术研究ＨＩＶｗｔ及ＨＩＶＧｌｕ与脂的相互作用。荧光淬灭实验表明ＨＩＶｗｔ插入带负电磷脂并插入较深;而ＨＩＶＧｌｕ虽然能与带负电脂结合但并不插膜。单层膜实验进一步证实了上述结果：ＨＩＶｗｔ对带负电磷脂ＰＯＰＧ的临界插膜压达到４３ｍＮ／ｍ,而ＨＩＶＧｌｕ的临界插膜压只有３１ｍＮ／ｍ。这提示ＨＩＶｗｔ与单层膜不仅存在静电作用还有较强的疏水作用。结合上述实验结果推测ＨＩＶｗｔ能插入脂膜的酰基链因而容易促发融合;而ＨＩＶＧｌｕ插膜很浅或根本不能入膜从而不能促融合     

腮腺炎病毒F蛋白七肽重复序列的表达、纯化及特性分析

副粘病毒F蛋白的两段七肽重复序列（HR1和HR2）在病毒侵染细胞的过程中相互作用形成热稳定的富含α螺旋的异源二聚体,此结构的形成引起病毒囊膜与细胞膜的并置而最终导致膜融合的发生。腮腺炎病毒（Mumps virus, MuV）属于副粘病毒科,腮腺炎病毒属,可能利用与其他副粘病毒相似的侵染机制。本研究对MuV 融合蛋白的HR区进行了计算机程序预测,并利用大肠杆菌GST融合表达系统对MuV F蛋白HR1和HR2两段多肽进行了表达和纯化,通过GST pull_down 实验证实HR1和HR2多肽在体外能够相互作用,凝胶过滤层析证明HR1、HR2多肽能够形成多聚体,说明MuV F蛋白的HR区的相互作用可能是其发挥融合功能的关键因素。     

Rational design of highly potent HIV-1 fusion inhibitory proteins: implication for developing antiviral therapeutics

Recombinant protein containing one heptad-repeat 1 (HR1) segment and one HR2 segment of the HIV-1 gp41 (HR1-HR2) has been shown to fold into thermally stable six-helix bundle, representing the fusogenic core of gp41. In this study, we have used the fusogenic core as a scaffold to design HIV-1 fusion inhibitory proteins by linking another HR1 to the C terminus of HR1-HR2 (HR121) or additional HR2 to the N terminus of HR1-HR2 (HR212). Both recombinant proteins could be abundantly and solubly expressed and easily purified, exhibiting high stability and potent inhibitory activity on HIV-1 fusion with IC50 values of 16.2+/-2.8 and 2.8+/-0.63 nM, respectively. These suggest that these rationally designed proteins can be further developed as novel anti-HIV-1 therapeutics.     

Characterization and HIV-1 fusion inhibitory properties of monoclonal Fabs obtained from a human non-immune phage library selected against diverse epitopes of the ectodomain of HIV-1 gp41

Using a human non-immune phage library comprising more than 10(9) functional human antibody specificities in Fab format, we have been able to select a set of eight monoclonal Fabs targeted against diverse epitopes of the ectodomain of gp41 from HIV-1. The antigens used for panning the antibodies comprised two soluble, disulfide-linked, trimeric polypeptides derived from gp41, N(CCG)-gp41 and N35(CCG)-N13. The former comprises an exposed trimeric coiled-coil of the N-helices of gp41 fused in helical phase to the minimal thermostable ectodomain of gp41, while the latter comprises only the trimeric coiled-coil of N-helices. The selected Fabs were probed by Western blot analysis against four antigens: N(CCG)-gp41, N35CCG-N13, N34CCG (a smaller version of N35CCG-N13), and the minimal thermostable ectodomain core of gp41 in its six-helix bundle conformation (6-HB). Three classes of Fabs were found: class A (two Fabs) interact predominantly with the 6-HB; class B (four Fabs) interact with both the 6-HB and the internal trimeric coiled-coil of N-helices; and class C (two Fabs) interact specifically with the internal trimeric coiled-coil of N-helices. The IC50 values for the Fabs, expressed as bivalent mini-antibodies, ranged from 6 microg/ml to 60 microg/ml in a quantitative vaccinia virus-based reporter gene assay for HIV-1 envelope-mediated cell fusion using the envelope from the HIV-1 T tropic strain LAV. The two most potent fusion inhibitors belonged to class B. This panel of Fabs provides a set of useful probes for studying HIV-1 envelope-mediated cell fusion and may serve as a basis for developing Fab-based anti-HIV-1 therapeutics.     

Design, synthesis, and biological activity of a novel series of 2,5-disubstituted furans/pyrroles as HIV-1 fusion inhibitors targeting gp41

Based on molecular docking analysis of earlier results, we designed a series of 2,5-disubstituted furans/pyrroles (5a-h) as HIV-1 entry inhibitors. Compounds were synthesized by Suzuki-Miyaura cross coupling, followed by a Knoevenagel condensation or Wittig reaction. Four of these compounds were found to be effective in inhibiting HIV-1 infection, with the best compounds being 5f and 5h, which exhibited significant inhibition on HIV-1(IIIB) infection at micromolar levels with low cytotoxicity. These compounds are also effective in blocking HIV-1 mediated cell-cell fusion and the gp41 six-helix bundle formation, suggesting that they are also HIV-1 fusion inhibitors targeting gp41 and have potential to be developed as a new class of anti-HIV-1 agents.     

Design and synthesis of novel pyrimidone analogues as HIV-1 integrase inhibitors

A series of novel pyrimidone analogues have been designed and synthesized as HIV-1 integrase (IN) inhibitors. This study demonstrated that introducing a substituent in the N1-position of the pyrimidone scaffold does not significantly influence IN inhibitory activity. Molecular docking studies showed these compounds could occupy the IN active site and form pi–pi interactions with viral DNA nucleotides DC16 and DA17 to displace reactive viral DNA 3′OH and block intasome activity.     

A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase

The retroviral encoded protein integrase (IN) is required for the insertion of the human immunodeficiency virus type 1 (HIV-1) proviral DNA into the host genome. In spite of the crucial role played by IN in the retroviral life cycle, which makes this enzyme an attractive target for the development of new anti-AIDS agents, very few inhibitors have been described and none seems to have a potential use in anti-HIV therapy. To obtain potent and specific IN inhibitors, we used the two-hybrid system to isolate short peptides. Using HIV-1 IN as a bait and a yeast genomic library as the source of inhibitory peptides (prey), we isolated a 33-mer peptide (I33) that bound tightly to the enzyme. I33 inhibited both in vitro IN activities, i.e. 3' end processing and strand transfer. Further analysis led us to select a shorter peptide, EBR28, corresponding to the N-terminal region of I33. Truncated variants showed that EBR28 interacted with the catalytic domain of IN interfering with the binding of the DNA substrate. Alanine single substitution of each EBR28 residue (alanine scanning) allowed the identification of essential amino acids involved in the inhibition. The EBR28 NMR structure shows that this peptide adopts an alpha-helical conformation with amphipathic properties. Additionally, EBR28 showed a significant antiviral effect when assayed on HIV-1 infected human cells. Thus, this potentially important short lead peptide may not only be helpful to design new anti-HIV agents, but also could prove very useful in further studies of the structural and functional characteristics of HIV-1 IN.     

Design,synthesis and biological evaluation of HIV-1 protease inhibitors with morpholine derivatives as P2 ligands in combination with cyclopropyl as P1′ ligand

A series of novel HIV-1 protease inhibitors has been designed and synthesized, which contained morpholine derivatives as the P2 ligands and hydrophobic cyclopropyl as the P1′ ligand at the meantime in this study, with the aim of improving the interactions between the active sites of HIV-1 protease and the inhibitors. Twenty-eight compounds were synthesized and assessed, among which inhibitors m18 and m1 exhibited excellent inhibitory effect on the activity of HIV-1 protease with IC₅₀ value of 47 nM and 53 nM, respectively. The molecular modeling of m1 revealed possible hydrogen bondings or van der Waals between the inhibitor and the protease, worthy of in-depth study.     

Role of Glycosphingolipids in HIV-1 Entry: Requirement of Globotriosylceramide (Gb3) in CD4/CXCR4-dependent Fusion

We have recently shown that addition of human erythrocyte glycosphingolipids (GSL) to non-human CD4⁺ or GSL-depleted human CD4⁺ cells rendered those cells susceptible to gp120-gp41-mediated cell fusion (Puri et al., BBRC, 1998). One GSL fraction (Fraction 3) isolated from human erythrocyte GSL mixture exhibited the highest recovery of fusion following incorporation into CD4⁺ non-human and GSL-depleted HeLa-CD4 cells (HeLa-CD4/GSL^–). Structural analysis of Fraction 3 showed that this GSL had identical head group as the known GSL, Gal(14)Gal(1 4)Glc-Ceramide (Gb3) (Puri et al., PNAS, 1998). Here we report that presence of Gb3 in CD4⁺/CXCR4⁺ cells but not CD4⁺/CXCR4^– cells allows fusion with HIV-1_Lai-envelope glycoprotein expressing cells (TF228). Therefore, Gb3 functions in conjunction with HIV-1 co-receptor, CXCR4 to promote fusion. We propose that Gb3 functions by recruiting CD4 and/or CXCR4 at the fusion site through structurally specific interactions.     

HIV-1 protease regulation: The role of the major homology region and adjacent C-terminal capsid sequences

The maturation of human immunodeficiency type-1 virions is accomplished through the proteolytic processing of Gag and GagPol precursor proteins by the viral protease (PR). Since virions must be assembled at the cell surface from uncleaved precursor molecules, intracellular activation of PR must be inhibited. We have previously developed a system where the intracellular activity of PR, associated with GagPol, was inhibited by the expression of Gagin trans. The disproportionate synthesis of Gag inhibits the activation of PR in the cytoplasm. Sequences capable of mediating this inhibition were localized to capsid. In this communication, the region of HIV-1 capsid capable of mediating inhibition was further defined and shown to require the major homology region of capsid within Gag.